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Abstract 
Prostaglandins (PGs) are medicinally interesting because of the wide variety of 
roles they play in the body. PGs are ubiquitous and can be found in the reproductive 
system, the nervous system, the cardiovascular system, and the immune system. 
Accordingly, PGs are an important therapeutic target for pharmaceutical companies, and 
an efficient synthesis is highly desirable. Past research indicates that an approach to 
prostaglandins via a chiral acetylenic ester or amide provides a promising method for 
control of C-15 geometry. This project seeks to validate a key stereospecific reduction of 
an enantiomerically pure cyclopentenone intermediate. This is in turn available from a 
chiral acetylenic ester or amide via a formal [3+2] cycloaddition step. Several methods 
have been investigated for asymmetric synthesis of the requisite chiral acetylenic acid 
derivative including asymmetric conjugate addition, CBS-oxazaborolidine reduction of a 
ketone, and the separation of diastereomers of a chiral amide. With the optically pure 
cyclopentenone in hand, we will investigate hydroxyl directed conjugate reduction of the 
cyclopentenone double bond as shown in the figure. 
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 1 
Introduction 
Prostaglandins (PGs) are medicinally interesting due to their broad spectrum of 
biological activity.  PGs act in many parts of the body, including (but not limited to): the 
reproductive system (in both males and females), the nervous system, the cardiovascular 
system, the immune system and gastrointestinal system.1  Due to their diverse biological 
activity, there is potential for prostaglandin analogs (prostanoids) to function as effective 
therapeutic agents.  Indeed, there are already PG analogs used as drugs for the treatment 
of ulcers, hypertension and other conditions.   
In the 1960’s and 1970’s, soon after the core structure of the PGs was determined, 
many different routes for prostaglandin synthesis were explored.2,3  However, achieving 
an asymmetric synthesis of the PGs still presents unique challenges.  A wide variety of 
strategies have been employed, however further investigation is still warranted.  
Development of a robust, asymmetric route to prostaglandins would greatly benefit 
development of prostanoids by pharmaceutical companies.   
Structure 
In the most basic sense, PGs are twenty-carbon molecules made up of a five-
membered (cyclopentane) ring with two aliphatic sidechains.  The numbering of these 
molecules is straightforward, and is shown in representative example 1 (Figure 1).  Two 
other structural features are found in all prostaglandins:  C-15 is a stereo center with an 
attached hydroxyl group, and C-9 always has an attached oxygen function (present as a 
hydroxyl group, ketone, or part of a bridged peroxide moiety).  There are a few other 
distinguishing characteristics of PGs that are not ubiquitous:  In most cases, the carbons 
to which the side chains are attached are stereo centers, and some PGs have a second 
oxygen function attached to either the C-10 or C-11 positions.  Also, PGs can have up to 
three double bonds present in the sidechains.  These structural details separate the known 
prostaglandins into nine families (or “classes”), while the absence or presence of double 
bonds in the sidechains separates the PGs into three “series”. 
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Figure 1. Prostaglandin A2 
As mentioned, prostaglandins are categorized into “series” and “classes”.  The 
“series” classification divides PGs up by general structural elements conserved across all 
classes of prostaglandin as well as indicating from which fatty acid the PG is derived.  
The “classes” categorize different types PGs by their specific structural elements. 
There are three series of prostaglandins, labeled as: PGX1, PGX2 and PGX3, 
where “X” is a letter indicating the class of a given prostaglandin.  The subscripts 
indicate the number of double bonds in the side chains coming off of C-8 and C-12, 
which indirectly indicates from what precursor a PG has been generated.  Prostanoids are 
derived from certain essential fatty acids, which are known as the eicosanoic acids.  Each 
series of prostaglandin is derived from a different eicosanoic acid:  the 1-, 2-, and 3- 
series are derived from dihomo-γ-linolenic acid, arachidonic acid (2), and 5, 8, 11, 14, 
17-eicosapentaenoic acid respectively (Figure 2).  The 1-, 2-, and 3- series, “class A” 
prostaglandins (also known as “PGAs”) are shown below in Figure 3 were derived from 
the corresponding fatty acid in Figure 2.   
COOH
 
dihomo-γ-linolenic acid 
COOH
 
arachidonic acid (2) 
COOH
 
5,8,11,14,17-eicosapentaenoic acid 
Figure 2. C-20 Fatty Acid PG Precursors 
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Figure 3. PGA1, PGA2, PGA3 Left to Right 
There are nine common classes of prostaglandins, each defined by specific 
structural elements, named arbitrarily as PGA through PGI.  Each class of prostaglandin 
contains a set of 3 molecules analogous to the PGA series in Figure 3; the 1-series is 
shown for the rest of the classes of PGs (Figure 4). Precisely one diastereomer of these 
compounds is found in nature, indicating the importance of the stereochemistry, 
especially with respect to the C-15 position.  Several structural properties are conserved 
between the various classes of PG. 
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Figure 4. Classes of Prostaglandins 
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Biosynthesis 
Biosynthesis of PGs is often initiated by stimulation (physical, chemical, or 
neural), and synthesis generally occurs in the region where the PG is to exert influence.  
For example, one study showed that when guinea pig lung strips are gently rubbed, a 
large amount of certain types of prostaglandin are released and cause a number of varied 
responses from the tissue. 4  After stimulation, the concentration of prostaglandins present 
is much greater than the amount of PG that can be isolated from lung tissue without 
stimulation, indicating that the prostaglandin is being synthesized on-site.  The cycle of 
synthesis to metabolism in vivo is rapid:  the prostaglandins are synthesized, exert their 
influence over a few minutes, and are subsequently metabolized.1   This rapid metabolism 
accounts for low equilibrium concentrations of PG in vivo.  When PGE1 and/or PGE2 are 
passed once through cat, dog, rabbit or guinea pig lung, about 90% of the biological 
activity is lost.5  In contrast, seminal fluid is one of the only areas where stores of 
prostaglandins are held.  The concentration of PGs in seminal fluid can reach several 
hundred μg/mL, but in most other tissues, the concentrations are 106 times lower.6  In the 
late 1960’s and early 1970’s the biosynthesis of prostaglandins in the 2-series was studied 
closely.  Since then, the biosynthesis of PG2s has served as a model for the biosynthesis 
of other PGs and related compounds.1,7   
Prostaglandin biosynthesis depends on the availability of the requisite fatty acid.  
Like many fatty acids, eicosanoic acids are stored mainly as phospholipids in the cell 
membrane.  The release and subsequent metabolism of arachidonic acid (2) has been well 
studied.  A stimulus or hormone outside the membrane of the cell leads to activation of 
the enzyme phospholipase A2 (PLA2), shown in Figure 5. Biosynthesis (Modified from 
Ref. 7).  Upon activation, PLA2 cleaves specific ester bonds of phospholipid molecules, 
releasing arachidonic acid.   
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Figure 5. Biosynthesis (Modified from Ref. 7) 
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Once released, arachidonic acid (2) is acted upon sequentially by two enzymes: a 
cyclooxygenase and a peroxidase (collectively known as “prostaglandin synthase”).  The 
cyclooxygenase enzyme begins to develop the structure of the future prostaglandin; the 
familiar five-membered ring with trans-stereochemistry is formed, and two molecules of 
oxygen are added to the molecule to form the intermediate PGG2.  The first molecule of 
oxygen exists in the form of an endoperoxide, while the second molecule of oxygen is 
added (stereospecifically) as a peroxide group in the C-15 position.  The second enzyme, 
a peroxidase, converts the C-15 peroxide group in to a C-15 hydroxyl group leading to 
PGH2 which is both a naturally occurring prostaglandin with its own biological effects 
and a precursor for further biological derivation. 
Once the action of the prostaglandin synthase machinery is complete, the newly 
formed PGH2 may be acted on by other enzymes, such as the PGD2 or PGE2 synthases to 
create the other classes of prostaglandin. 
Previous Work 
Previous research8 in the laboratory of Professor Dittami has afforded a fairly 
efficient route to a prostaglandin core (3) framework (Figure 6).  Key points to note in the 
structure are the stereo center at C-15 positiona, the trans-stereochemistry across the bond 
between C-8 and C-12 positions, and the ester function at position 8 which serves as a 
precursor to the C1-C7 sidechain.  The stereo centers are common to many PGs and are 
important to their biological activity, while the ester on C-8 provides a versatile handle 
for later conversion to analogs. 
O
C5H11
HO
O
OEt
8
12 15
3  
Figure 6. Desired Prostaglandin Core 
The retrosynthetic approach is shown below in Scheme 1. In Step 4, a 
stereospecific [3,3] sigmatropic shift moves the hydroxyl group from the C-13 position to 
the C-15 position with retention of configuration, providing 3, the desired core structure.  
                                                 
a For simplicity, the same numbering is used for both PGs and for this desired PG core. 
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Step 3 employs stereospecific reduction of the double bond in the ring, directed by the 
hydroxyl group on the C-15 stereocenter, yielding 4.  A formal [3+2] cycloaddition of a 
chiral acetylenic ester creates the substituted cyclopentenone ring in Step 2 (5). 9  Step 1 
involves formation of an enantiomerically pure chiral acetylenic ester or amide (6).  
Racemic 6 is easily obtained from the commercially available starting materials ethyl 
propiolate (7) and trans-2-octenal (8).  Steps 4 and 2 have been previously carried out 
and optimized using racemic mixtures or model compounds with good yields.  Previous 
attempts to asymmetrically synthesize the acetylenic ester intermediate 6 in Step 1 have 
resulted in inadequate enantiomeric excess (ee).  Because of this, the stereospecificity in 
Step 3 remains to be proven, and is therefore the focus of this and future research. 
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Step 1 O
O
H
H
O
C5H11
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3 4 5
6 7 8  
Scheme 1. Retrosynthesis 
Establishing the Latent C-15 Hydroxyl Stereochemistry 
A key element of our synthesis is to establish the stereochemistry of the hydroxyl 
center in acetylenic ester 6.  This functional group is expected to serve two roles. (1) It 
can participate in directing the reduction of the double bond in 5, giving rise to two new 
stereo centers at C-8 and C-12. (2) It serves as latent functionality for the C-15 
stereocenter via [3,3] sigmatropic shift.  The stereochemical integrity of the C-15 center 
is vital for the biological activity of the PG’s.  Previous strategies for obtaining this 
intermediate included derivatization of the racemic intermediate by attaching a chiral 
group to the hydroxyl moiety (followed by separation of diastereomers), reduction of the 
corresponding ketone with Alpine borane, and taddol-assisted asymmetric addition of 
ethyl propiolate (7) to trans-2-octenal (8).  None of these methods, however, provided the 
intermediate with both adequate yield and ee. 
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Figure 7. Key Chiral Acetylenic Ester Intermediate 
The proof of concept for synthesis of 3 via 6 (Scheme 1) has been demonstrated 
using racemic acetylenic ester 6 (Scheme 2), which is easily obtained via a two-step one 
pot coupling.  The alkyne 7 is deprotonated by lithium diisopropyl amide (LDA) to yield 
the lithiated species 7a, which upon addition of the aldehyde 8 gives rise to racemic 
intermediate 6.  This coupling step has been carried out with yields up to 93%. 
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O
O
Li7 7a
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8
 
Scheme 2. Racemic Alcohol 
Formal [3+2] Cycloaddition 
 Acetylenic alcohol 6 is employed in formation of pentacyclic ester 5 via a formal 
[3+2] cycloaddition developed in the laboratory of Michael Crimmins.  This step has 
been carried out providing yields of 85% or greater.  The key step is the pre-formation of 
a zinc homoenolate from a cyclopropyl ether and ZnCl2, which is then added to racemic 6 
in the presence of HMPA and CuBr.Me2S (Scheme 3).  Catalytic transmetallation by the 
copper (I) bromide complex converts the zinc homoenolate into a cuprate.  A Michael 
addition of the homoenolate to the acetylenic ester occurs, followed by cyclization 
providing racemic 5.   
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Scheme 3. [3+2] Cycloaddition (Adapted from Ref. 9) 
 This cyclization provides an elegant route to 2, 3-disubstituted cyclopentenones, 
which have been historically difficult to synthesize.  The hydroxyl-bearing stereocenter in 
the molecule can now be used to direct a reduction across the double bond in the ring. 
Stereospecific Reduction 
This step provides two synthetic challenges: The reduction must be specific for 
the double bond in the ring and it must also be regio- and stereospecific.  The conjugate 
reduction of a racemic mixture of a cyclopentenone starting material could conceivably 
give rise to eight products (four cis-products, and four trans-products).  However, there is 
ample precedent to show that formation of trans-products occurs predominantly if not 
exclusively.10  Thus, four possible products were anticipated (Scheme 4). 
In previous work, the conjugate reduction of the trimethylsilyl (TMS) protected 
alcohol (5) was investigated.  Several types of reduction conditions were examined, but 
lithium aluminum hydride and copper (I) iodide in ether or tetrahydrofuran (THF) were 
found to give the best stereoselectivity for the desired products.  These conditions 
provided up to 98% overall yield.   In Scheme 4, the desired pair of enantiomers are 
shown as compounds 4 and 4b, and the undesired pair of enantiomers are shown as 
compounds 4c and 4d.  In previous work carried out in our laboratory, Cruz reported that 
99.5% was recovered as the desired product and 0.5% as undesired product (Ref.8, pg 
171).  These two sets of diastereoisomers are separable by normal chromatographic 
methods and are distinguishable by NMR.  The diastereomeric excess was determined by 
relative integrations in the 1H NMR spectrum of the crude mixture.  The absolute 
configurations of each pair of enantiomers were determined by nOe coupling patterns on 
the pure compounds. 
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Scheme 4. Stereospecific Reaction Conditions 
 The proposed intermediate (9) for the reaction is shown in Figure 8.  The lithium 
aluminum hydride and copper bromide react to form a copper hydride species which 
complexes the TMS-ether oxygen in the C-13 position.  The complex positions a hydride 
group in an ideal position for the reduction.   
O
C5H11
O
O
O
SiMe3Cu
H
H
9  
Figure 8. Copper Hydride Complex Directing Reduction (Adapted from Ref. 8) 
However, if the oxygen bearing sidechain is not rotationally constrained, the 
reduction can occur from both faces of the cyclopentenone ring.  Given enantiomerically 
pure starting material, this would lead to two diastereomeric products (Figure 9).  The 
experimental evidence reported above suggests that a conformation leading mainly to 
only one of the diastereomers is preferred. The two possible diastereomeric products 4 
and 4c are shown in Figure 9.  As noted above, the reduction of racemic 5 provided 
mainly product 4.  By extension a reaction on only one enantiomer should have the same 
distribution of products as in the reaction with a racemic mixture product: 99.5% desired 
product 4 and 0.5% undesired diastereomer 4c. 
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Figure 9. Diastereomeric Products Formed by the Reduction 
Stereoselective [3,3] Sigmatropic Shift 
The last step of the synthesis is a stereospecific [3,3] sigmatropic rearrangement 
of 4 to 3 to establish the C-15 hydroxyl with correct stereochemistry.  This reaction is 
performed using the acylated alcohol.  This rearrangement is known to provide product 
with retention of configuration (Scheme 5).11  It proceeds via a concerted mechanism 
involving a six-electron rearrangement.  Previous results have shown that the yields are 
relatively good (70%), and that remaining starting material can be recovered for further 
use.  
O
O C5H11
OEt
O
O
[Pd(MeCN)2]Cl2
THF
O
O C5H11
OEt
O
O
1513
4 3  
Scheme 5. [3,3] Sigmatropic Shift 
Current Work 
 The key point of optimization for our PG synthesis is to obtain the intermediate 6 
in high yield and good stereochemical purity so that it can be cyclized and used to test the 
stereospecificity of the reduction of 5 to 4.  Current work in our laboratory involves 
investigation of several methods for obtaining the intermediate 6 or a similar acetylenic 
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acid derivative 10 (Figure 10).  The methods used are broken down into two categories: 
direct asymmetric synthesis and separation of diastereoisomers. 
X
O
OH
C5H11
10
R
X = -NH-, -O-
R =Alkyl
 
Figure 10. Acetylenic Acid Derivative 
Advantages of the separation of stereoisomers include ease of separation (eg. 
conventional chromatography) and reactions that are relatively insensitive to water and 
air.  The obvious disadvantage: the maximum yield of the desired enantiomer is only 
50% (Scheme 6).  In this case, however, it is worth investigation: even a small amount of 
the intermediate can be used to show stereospecificity in the conjugate reduction of 5 
(Scheme 4).  Two methods for separation of stereoisomers are being investigated: 
selective deacylation of the intermediate 6 by the commercially available enzyme 
Novozym 435 and separation of the diastereomers of a chiral acetylenic amide 
intermediate. 
R
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C5H11
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R
O
OH
C5H11
R
O
OH
C5H11
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50%
50%
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Scheme 6. Separation of Stereoisomers 
Novozym 435 consists of a lipase isolated from Candida antarctica bound to a 
solid phase.  Past research on the lipase in Novozym 435 has shown that the similar 
substrate 11 undergoes stereospecific deacylation of one enantiomer with good yield and 
ee (>95%) as shown in Scheme 7.12  
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Scheme 7. Similar Substrate in Novozym 435 Hydrolysis 
The binding site of the enzyme is composed of two pockets for different sized 
groups: one large and one small.  This binding pocket accommodates molecules of the 
general structure shown in Figure 11.  Based on this analysis, we thought that the 
intermediate 6 may fit into the binding pocket of the enzyme and undergo selective 
deacylation.13 
 
R1 R2
OH
R1= long aliphatic chain (5-11 carbons)
R2= short chain (1-2 carbons)
*
 
Figure 11. General Structure of Novozym 435 Substrates 
 Intermediate 6 was acylated with acetic anhydride and pyridine yielding 13 
(Scheme 8).14 The acylated intermediate 13 was then subjected to deacylation by the 
enzyme.  The first set of reaction conditions used aqueous buffer as a solvent.  The 
intermediate 13 is not miscible with water, so the contact between the enzyme (on solid 
beads, freely moving in the solution) and the substrate was minimal and no reaction 
occurred.  To bring the substrate and the enzyme together, we found similar papers 
reporting deacylation in organic media.15  With these conditions, the substrate was 
dissolved in solution, and there was good contact between the substrate and the enzyme, 
but no reaction occurred.  This result may have been due to interference from the ester 
group in the pocket of the enzyme, as the other compounds reported generally contained 
only one ester function.  At this point, other options were explored, although resolution of 
11 and subsequently adding the ester function is a possibility that may be worth some 
attention.   
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Scheme 8. Acylation 
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Scheme 9. Novozym 435 Reaction Conditions 
The other separation method being explored involves the use of a chiral acetylenic 
amide to add a built-in optically pure stereo center.  Previous studies have focused on an 
acetylenic ester intermediate, but using an acetylenic amide intermediate is also possible.  
Use of acetylenic amides in the construction of disubstituted cyclopentenones (Scheme 
10) has been carried out.  Reportedly, the yields are improved with these systems.9 
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Scheme 10. Cycloaddition with Amides 
Using propiolic acid 14 and 1-phenylethanamine 15 in conventional amide bond 
forming chemistry provides the chiral substituted acetylene 16 (Scheme 11).16  Both 
enantiomers of 15 are commercially available and inexpensive.  Once formed, the 
acetylene 16 can then be taken on via addition to trans-2-octenal (8).  There are, 
however, two acidic protons in 16: the proton on the nitrogen and the acetylenic proton.  
Literature searching reveals that two equivalents of LDA will completely remove both of 
these protons to give a dianion.  When an aldehyde such as 8 is added to the reaction 
mixture, addition occurs via attack of the acetylenic carbon on the aldehyde center as 
shown for the conversion of the similar compound 17 to 18 in Scheme 12.17  This method 
is still being examined in our laboratory.  We have thus far synthesized 16, although in 
low yield.  Optimization of the reaction to form 16 (Scheme 11), followed by addition of 
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acetylene 16 to 8 may provide an easily separable set of diastereomers that can be 
resolved and taken on to the cyclization and reduction steps (Scheme 13). 
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Scheme 11. Formation of Chiral Acetylene 
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Scheme 12. Addition (Adapted from Ref. 17) 
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Scheme 13. Proposed Synthesis of 16a 
 Direct asymmetric synthesis of 6 has the distinct advantage of 100% maximum 
yield.  Two methods were investigated: asymmetric addition of an alkyne to an aldehyde 
and asymmetric reduction of the ketone of 19 (Scheme 14).  Literature searches on 
asymmetric addition lead to work done in the laboratory of E.M. Carreira.18  Using N-
methyl ephedrine as a chiral auxiliary, Carreira has shown that a number of both 
substituted and unsubstituted acetylenes undergo asymmetric addition to aldehydes.19,20  
In a well-known reaction pioneered by E.J. Corey, ketones such as 19 undergo 
asymmetric reduction directed by chiral oxazaborolidines in the presence of a reducing 
agent such as borane-dimethylsulfide.21  This reaction has since been used in 
stereospecific syntheses of natural products such as discodermolide and petrofuran.22,23 
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Scheme 14. Direct Asymmetric Synthesis 
 Using the work of Carreira as a guide, we attempted the addition of ethyl 
propiolate 7 to trans-2-octenal 8 to synthesize intermediate 6 directly (Scheme 15).  
Formation of product was not observed.  Carreira noted improved performance with the 
acetylene 2-methylbut-3-yn-2-ol (20) in this addition. Furthermore, he devised 
fragmentation conditions for removal of the acetylenic substituent, providing 
unsubstituted propargylic alcohols (Scheme 16).20  Attempts to add the Zn-alkynilide of 
20 to aldehyde 8 however, did not result in formation of the desired product.  Though 
reactions using unsubstituted aliphatic aldehydes have been reported, the yields are lower 
than reactions using shorter substituted aliphatic aldehydes or cyclic aldehydes. 
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Scheme 15. Direct Synthesis of 6 
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Scheme 16. Route to Unsubstituted Propargyl Alcohols (From Ref. 20) 
 As a check on our technique, we attempted to repeat one of the reactions reported 
in the Carreira paper.  The addition of acetylene 20 to benzaldehyde (21) had been 
reported to provide propargyl alcohol 22 in quantitative yield.  This reaction was repeated 
successfully in our laboratory, indicating that the aldehyde 8 was the source of the trouble 
in our reactions.  We concluded that the aldehyde 8 does not easily submit to this type of 
addition and other methods were explored. 
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Scheme 17. Addition of Acetylene 20 to Benzaldehyde 
 Asymmetric reduction of acetylenic enones such as 23 by oxazaborolidines has 
been reported previously, and there is ample precedent for the successful reduction of 
compounds similar to our compound 19 (Figure 12).22,23 However, commercially 
available oxazaborolidine catalyst is relatively expensive, so a model compound was 
employed to optimize the reaction conditions.  The reduction of similar enone 23 has 
been reported in quantitative yield and 95% ee.24  It should be noted that the 
trimethylsilyl (TMS) group can be easily removed and replaced with the desired ester 
function.  As a model compound, we chose a hybrid between the desired compound 19 
and the known compound 23.  In the model compound 24, the length of the aliphatic 
chain on the aldehyde is preserved from 19 and the TMS group from 23 is retained 
(Figure 12). 
O
C5H11
TMS 24
O
C3H7
TMS 23
O
C5H11
EtO2C 19
 
Figure 12. Similar Enone, Model Compound and Desired Compound 
Compound 24 was obtained via oxidation of racemic alcohol 26 either by 
manganese oxide or Jones’ reagent.25,26  Compound 26 was prepared in turn from n-butyl 
lithium promoted addition of trimethylsilylacetylene to trans-2-octenal (8).24  Product 24 
was subjected to reduction by (S)-2-methyl-CBS-oxazaborolidine 25 and borane-
dimethylsulfide quantitatively yielding the enantioenriched alcohol 26.  The absolute 
configuration and ee of this compound were determined using the modified Mosher 
method as described below.27   
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Scheme 18. Asymmetric Reduction of 24 
 According to the modified Mosher method reported by Ohtani27, the (R)- and (S)- 
2-methoxy-2-phenyl-2-(trifluoromethyl)acetic acid (MTPA) esters of 26 were produced 
from the appropriate commercially available MTPA acid chlorides (Scheme 19).  It has 
been shown that MTPA esters adopt a preferred eclipsed conformation creating an 
“MTPA plane” (Figure 13).  Of note is the relative position of the phenyl ring to the 
substituents on either side of the MTPA plane.  The diamagnetic effect of the benzene 
ring in the MTPA ester causes shifting of proton signals.  In one compound, the phenyl 
ring will affect the trimethylsilyl acetylene substituent and in the other, the effect will be 
on the unsaturated aliphatic chain.  Calculations using the difference between the proton 
signals for the corresponding hydrogens in each enantiomer of the ester provide enough 
evidence for assignment of absolute stereochemistry.  Integration of the methoxy singlets 
due to each enantiomer of 24 in either the R- or S- ester provides the enantiomeric excess.  
NMR shift data for our mixture was consistent with the absolute stereochemistry shown 
for 26 with an ee of 80%. 
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Scheme 19. Formation of MTPA Esters 
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Figure 13. MTPA Plane (From Ref. 27) 
 With this result in hand, the desired compound 19 has been oxidized with Jones’ 
reagent.  Studies of the asymmetric reduction of 19 to the desired acetylenic intermediate 
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6 with the oxazaborolidine 25 are currently in progress.  The other pathway available 
from this result is the cleavage of TMS from 26 followed by introduction of the desired 
ester function for which there is ample precedent.24,28,29  Both methods are now available 
to create the key stereo center in the molecule.  With this in hand, studies on the 
asymmetric reduction in Step 3 can be carried out. 
 We next focused our attention on construction of the cyclopentenone core of the 
PGs via the aforementioned Crimmins procedure.9  Our intention was to employ chiral 
intermediate 26 or 6 to provide 5 which could be used to evaluate the proposed conjugate 
reduction (Scheme 20).  In an effort to evaluate and determine the optimum conditions 
for the Crimmins reaction, we employed the readily available racemic 6 (Scheme 21).  
Once we felt confident that the conversion of racemic 6 to racemic 5 went well, we could 
employ the more precious chiral reagents 26 or 6. 
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Scheme 20. Cyclization to Provide 5 
OEt
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Scheme 21. Cyclization 
 Initial attempts at the synthesis of racemic cyclopentenone intermediate 5 from 
racemic 6 failed.  To diagnose the problem, the inexpensive, commercially available 
model compound 27 was employed.  Methyl octynoate (27) was chosen both for its 
availability and for its similarity to methyl heptynoate, which was used in the original 
research in the laboratory of Dr. Crimmins (Scheme 22).  In our hands, the model 
compound 28 was produced in 12-15% yield, as compared to the 65% yield originally 
reported for a similar system by Crimmins. 
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Scheme 22. Cycloaddition using Methyl Octynoate (27) 
 Several factors could be responsible for the low yield.  Accordingly, we set out to 
systematically test each variable.  Suspecting the copper bromide complex may be bad, 
we attempted to synthesize and purify fresh material via the published procedure. 30,31  
Eventually we bought new commercially available copper bromide-dimethylsulfide 
complex which was colorless and appeared to be of good purity.  Unfortunately, yields 
for the reaction remained low. 
 With good copper bromide in hand and confident of the purity of our reaction 
solvents, we attempted to evaluate the first step – formation of zinc homoenolate 29 via 
sonication of (1-ethoxycyclopropyloxy)trimethylsilane (Scheme 23).  It has been reported 
that 29 is stable in deuterochloroform solution and can be analyzed by NMR.32,33 Thus, 
(1-ethoxycyclopropyloxy)trimethylsilane was sonicated in dry ether in the presence of 
zinc chloride.  Analysis by NMR, however, did not show formation of the expected 
homoenolate 29.32,33  A conversation with Dr. Crimmins confirmed our suspicion that 
perhaps the zinc chloride reagent was bad.34  Dr. Crimmins mentioned that in early 
iterations of the reaction, commercial zinc chloride solutions provided adequate 
formation of the homoenolate (29).  He went on to say that later reactions using 
commercial zinc chloride were unsuccessful, and laboratory prepared zinc chloride was 
used instead, with success.  The zinc chloride employed in our laboratory was obtained 
commercially as a 1 M solution in diethylether and had been recently purchased.  An 
equivalent solution can be made in the laboratory by fusing solid zinc chloride under 
vacuum and subsequently sonicating the solid with an appropriate amount of dry 
diethylether to facilitate dissolution.  Alternatively, new zinc chloride solution in ether 
can be purchased from a different vendor for use in the reaction.  Both methods are 
currently being tested in the laboratory. 
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Scheme 23. Formation of Zinc Homoenolate 
Future Work 
Future work will involve:   
(1) Preparation of optically pure 6 via either direct reduction of intermediate 19 or 
conversion of 26 (Scheme 24).35  
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Scheme 24. Preparation of Optically Pure 6 
(2) Optimization of the Crimmins conditions for preparation of 5 with racemic 6.   
(3) Synthesis of optically pure 5 from optically pure 6 (Scheme 21). 
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Scheme 20. Cyclization 
(4)  Evaluation of the asymmetric conjugate reduction of 5 to provide the cyclopentenone 
skeleton 4 (Scheme 25).   
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Scheme 25. Evaluation of Conjugate Reduction 
(5) Evaluation of the corresponding amide analogs of 6 in the overall synthesis plan.  
These are reported to provide better yields in the Crimmins procedure.  There are also a 
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number of readily available chiral amines which could be used for preparation of chiral 
amide intermediates 16a (Scheme 26). 
HOOC H
NH2
N
H
O
H
14
15
16
2 LDA
H
O
C5H11
8
N
H
O
16a OH
C5H11
 
Scheme 26. Creation of Chiral Amides 
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Experimental 
General Procedures 
 Solvents and chemicals were purchased from Aldrich and other local suppliers 
and were used as received (unless otherwise noted).  NMR Spectra were collected using a 
Bruker Avance 400 MHz spectrometer.  All spectra were acquired using CDCl3 as the 
solvent referenced to tetramethylsilane at δ 0.00 or to the isotopic impurity peak for the 
solvent.  FT-IR were acquired using a Perkin-Elmer Spectrum One ATR spectrometer.  
Flash chromatographic separations were done using JT Baker 400 mesh silica gel as the 
stationary phase.  All reactions were monitored by thin-layer chromatography on EM 
Science 60 F254 silica gel.  THF used as a solvent was freshly distilled under nitrogen 
from potassium with benzophenone as an indicator (unless otherwise noted).  Glassware 
for air and moisture sensitive reactions was flame dried, or oven dried at 120 °C for 2 
hours and purged with dry nitrogen prior to use (unless otherwise noted). 
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Synthesis of ethyl 4-hydroxyundec-5-en-2-ynoate (racemic 6) 
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Method A (Ref. 8) 
To a stirred solution of LDA (3.0 mL, 6.0 mmol) in THF (20 mL) at –78 °C under 
nitrogen was added dropwise a solution of ethyl propiolate (7) (1.1 mL, 1.1 g, 11 mmol) 
in THF (10 mL).  The brown solution was stirred for 30 minutes at –78 °C after which a 
solution of trans-2-octenal (8) (1.5 mL, 1.3 g, 10 mmol) in THF (5 mL) was added.  The 
reaction mixture was stirred at –78 °C until the aldehyde was consumed as observed by 
TLC (9:1 hexane: ethyl acetate).  A saturated solution of ammonium chloride (5 mL) was 
added and the mixture was allowed to warm to room temperature.  The organic phase was 
concentrated under reduced pressure and dissolved in ethyl ether (10 mL).  The solution 
was washed with water and brine and dried over MgSO4.  The crude product was purified 
by flash chromatography (9:1 hexane: ethyl acetate) to yield 6 as a yellow oil (0.39 g mg, 
17%).  FT-IR (ATR) 3400 cm-1 (OH); 3100 cm-1 (C=C-H); 1750 cm-1 (C=O); 1050 cm-1 
(C-O-C).  1H NMRb (CDCl3, 400 MHz): δ 0.80 (t, 3H, J = 8 Hz); 1.18-1.28 (m, 11 H); 
4.18 (q, 2 H); 4.88 (s (br), 1 H); 5.49-5.55 (m, 1 H); 5.84-5.88 (m, 1 H). DEPT-135 13C 
NMR (CDCl3, 100 MHz): δ 14.42 (CH3), 14.45 (CH3), 22.90 (CH2), 28.79 (CH2), 31.78 
(CH2), 32.39 (CH2), 62.64 (CH2), 63.13 (CH), 127.1 (CH), 136.3 (CH). The NMR 
spectrum for the ethyl propiolate starting material is shown as A in the Appendix, the 
trans-2-octenal starting material is shown as B in the Appendix and the pure product 6 is 
shown as C in the Appendix. 
                                                 
b The 1H NMR and IR data for this compound agree with the data reported in reference 8, with the 
exception of the proton in the 1H NMR at δ 4.88, which was not reported previously. 
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Synthesis of ethyl 4-hydroxyundec-5-en-2-ynoate (racemic 6)  
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Method B 
To a stirred solution of LDA (1.6 mL, 2.8 mmol) in dry THF (1 mL) at –78 °C under 
nitrogen was added dropwise ethyl propiolate (7) (0.11 mL, 0.11 g, 1.1 mmol).  The 
brown solution was stirred for 30 minutes at –78 °C and trans-2-octenal (8) (0.15 mL, 
0.13 g, 1.1 mmol) was added dropwise.  The reaction mixture was stirred at –78 °C, and 
monitored by TLC (9:1 hexane: ethyl acetate) for disappearance of the aldehyde starting 
material.  After 40 minutes a saturated solution of ammonium chloride (0.5 mL) was 
added and the mixture was allowed to warm to room temperature.  The organic phase was 
extracted with ethyl ether (20 mL).  The combined organic phases were washed with 
water and brine and dried over MgSO4.  The crude product was purified by flash 
chromatography (9:1 hexane: ethyl acetate) to yield 6 as a light yellow oil (0.21 g, 94%). 
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Synthesis of ethyl 4-hydroxyundec-5-en-2-ynoate (racemic 6)  
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Method C 
To a flame dried round bottom flask was added dry tetrahydrofuran (10 mL) and ethyl 
propiolate (7) (1.0 mL, 10 mmol).  The clear solution was cooled to -78 °C and a 2.0 M 
of n-butyl lithium in cyclohexane (5.6 mL, 11 mmol) was added dropwise.  As the base 
was added, the solution turned from clear and colorless to dark brown.  The solution was 
allowed to stir at -78 °C for 10 minutes and trans-2-octenal (8) (1.2 mL, 8.2 mmol) was 
added dropwise.  The reaction mixture was stirred for 45 minutes and monitored by TLC 
(1:9 ethyl acetate: hexanes, p-anisaldehyde stain, UV light).  After 45 minutes, some of 
the aldehyde starting material remained.  The reaction mixture was warmed to room 
temperature after which it was poured over pH 7.0 phosphate buffer.  The organic layer 
was extracted with ether (2 x 50 mL) and the combined organic layers were washed with 
water and brine, dried over MgSO4. Solvent was removed under reduced pressure to give 
6 as a brown oil.  1H NMR of the crude oil showed that it contained desired product and 
aldehyde starting material.  The crude product was used directly in the next step without 
further purification. 
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Synthesis of ethyl 4-acetoxyundec-5-en-2-ynoate (13) 
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To a stirred solution of pyridine (0.75 mL) and acetic anhydride (0.25 mL) was added 
ethyl 4-acetoxyundec-5-en-2-ynoate (6) (0.12 g, 0.50 mmol).  The reaction mixture was 
allowed to stir at room temperature for one hour and was monitored by TLC (1:9 ethyl 
acetate: hexanes, uv light) for disappearance of starting material after which the reaction 
was cooled to 0 °C and saturated aqueous ammonium chloride solution was added.  The 
organic layer was diluted with ether, washed with ammonium chloride solution and brine, 
dried over magnesium sulfate.  Solvent was removed under reduced pressure and excess 
pyridine was removed by azeotropic distillation with toluene providing 13 as a brown oil 
(82 mg, 60%).  1H NMR (CDCl3, 400 MHz): δ 0.82 (t, 3H, J = 7.1 Hz); 1.19-1.35 (m, 11 
H); 2.00 (s, 3 H); 4.18 (q, 2 H); 5.42-5.48 (m, 1 H); 5.84 (d, 1 H, J = 6.8 Hz); 5.90-5.97 
(m, 1 H). The 1H NMR of this product is found in the Appendix as D. 
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Synthesis of (S)-4-methyl-1-phenylpent-2-yne-1,4-diol (22) 
(-)-N-methylephedrine
Zn(OTf)2, toluene, triethylamine
23 oC
OH
HHO
HO
O
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To an oven dried round bottom flask and stirbar was added zinc triflate (0.80 g, 2.2 
mmol) and (-)-N-methylephedrine (0.41 g, 2.3 mmol).  The flask was purged with dry 
nitrogen for 15 minutes after which toluene (6.0 mL) and triethylamine (0.23 g, 2.3 
mmol) were added.  The resulting suspension was stirred for 2 hours after which 2-
methylbut-3-yn-2-ol (20) (0.19 g, 2.3 mmol) was added.  The suspension was stirred for 
15 minutes followed by the addition of benzaldehyde (21) (79 mg, 0.74 mmol).  The 
mixture was stirred overnight after which saturated aqueous ammonium chloride (4 mL) 
was added.  The organic layer was extracted with ether (2 x 20 mL) and the combined 
organic phases were washed with brine and dried over MgSO4. Solvent was removed 
under reduced pressure to give the crude product as a yellow oil which was purified by 
flash chromatography (1:2 ethyl acetate: hexanes) to give 22 as a white solid (0.13 g, 
93%). mp 65-68 °C.  1H NMR (400 MHz, CDCl3): δ 1.57 (s, 6 H); 5.50 (s (br), 1 H); 
7.33-7.46 (m, 3 H); 7.54-7.56 (m, 2 H). The 1H NMR of benzaldehyde, 2-methylbut-3-
yn-2-ol and (-)-N-methylephedrine starting materials can be found in the appendix as E, 
F, and G respectively.  The 1H NMR of 22 can be found in the appendix as H. 
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Synthesis of 1-(trimethylsilyl)dec-4-en-1-yn-3-ol (racemic 26) 
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To an oven dried round bottom flask was added trimethylsilylacetylene (0.82 mL, 5.9 
mmol) and tetrahydrofuran (6 mL).  The solution was cooled to -78 °C and n-butyl 
lithium (2.5 mL, 5.0 mmol) was added dropwise.  The solution was stirred for 10 minutes 
after which trans-2-octenal (8) (0.75 mL, 5.0 mmol) was added dropwise.  After 10 
minutes, TLC analysis (2:1 dichloromethane: hexanes, p-anisaldehyde stain, UV light) 
revealed that the starting material had been consumed.  The reaction mixture was warmed 
to room temperature and poured into pH 7.0 phosphate buffer.  The organic layer was 
extracted with dichloromethane (2 x 20 mL), washed with brine and dried over Na2SO4.  
The solvent was removed to give the crude product as a light yellow oil (1.2 g, 92%).  1H 
NMR of the crude mixture showed that it contained a 1:5 mixture of aldehyde starting 
material to product.  The crude product (26) was taken to the next step without further 
purification.  1H NMR (CDCl3 400 MHz): δ 0.00 (s, 9 H); 1.10-1.40 (m, 11 H); 4.62-4.65 
(m, 1 H); 5.41-5.42 (m, 1 H); 5.67-5.72 (m, 1 H).  The 1H NMR of the 
trimethylsilylacetylene starting material and the product (26) can be found in the 
appendix as I and J respectively. 
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Synthesis of 1-(trimethylsilyl)dec-4-en-1-yn-3-one (24) 
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To a crude mixture of trans-2-octenal and 26 (1:5 mixture, 0.51 g total, 2.3 mmol) in 
hexanes (5.0 mL) was added MnO2 (2.7 g, 31 mmol).  The heterogeneous mixture was 
stirred overnight at room temperature.  TLC analysis (1:9 ethyl acetate: hexanes, p-
anisaldehyde stain, UV light) showed disappearance of the starting material.  The mixture 
was filtered through celite and the solvent removed to give the crude product as a yellow 
oil,  1H NMR of the crude mixture showed desired product, and trans-2-octenal left over 
from the previous step.  The product was purified by flash chromatography (1:9 ethyl 
acetate: hexanes) to yield 24 as a light yellow oil (0.12 g, 29% yield based on conversion 
of the starting material 26).  1H NMR (CDCl3 400 MHz): δ 0.28 (s, 9 H); 1.28-1.61 (m, 
11 H); 6.17 (d, 1 H, J = 15.8 Hz); 7.18-7.28 (m, 1 H).  The 1H NMR of the product 24 can 
be found in the appendix as K. 
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Synthesis of (S)-1-(trimethylsilyl)dec-4-en-1-yn-3-ol (26) 
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To an oven dried round bottom flask under argon at 0 °C was added tetrahydrofuran (2 
mL), a 1 M solution of (S)-2-methyl-CBS-oxazaborolidine in toluene (0.50 mL, 0.50 
mmol) and 2 M solution of borane-dimethyl sulfide in tetrahydrofuran (0.29 mL, 0.57 
mmol).  The mixture was stirred for 5 minutes at 0 °C and a solution of 1-
(trimethylsilyl)dec-4-en-1-yn-3-one (24) (0.12 g, 0.50 mmol) in tetrahydrofuran (1 mL) 
was added dropwise over 10 minutes.  Upon completion of addition, TLC analysis (1:9 
ethyl acetate: hexanes, p-anisaldehyde stain, UV light) revealed complete disappearance 
of the starting material.  The reaction was cautiously quenched with methanol (1 mL) at 0 
°C and then stirred for 15 minutes at room temperature.  Solvent was removed under 
reduced pressure to provide a viscous yellow oil.  1H NMR of the crude mixture showed 
formation of desired product.  The crude oil was purified by flash chromatography (1:9 
ethyl acetate: hexanes) to yield 26 quantitatively and with 80% ee.  1H NMR (CDCl3 400 
MHz): δ 0.0 (s, 9 H); 1.1-1.4 (m, 11 H); 4.62-4.65 (m, 1 H); 5.37-5.43 (m, 1 H); 5.68-
5.72 (m, 1 H).  The ee of the product was analyzed using the modified Mosher method.  
The 1H NMR data for the product, R-MTPA ester and S-MTPA ester are found in the 
appendix as L, M, and N respectively.   
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Synthesis of methyl 5-oxo-2-pentylcyclopent-1-enecarboxylate (28) 
MeO2C
OEt
OTMS
ZnCl2, ether, 
CuBr-Me2S
THF, HMPA
O
CO2Me27 28
 
To a flame dried round bottom flask under dry nitrogen was added dry ether (9 mL), (1-
ethoxycyclopropoxy)trimethylsilane (2.4 mL, 12 mmol), and a 1 M solution of ZnCl2 in 
ether (9.0 mL, 9.0 mmol).  The solution was sonicated for 40 minutes and stirred for an 
additional 10 minutes at room temperature.  To the heterogeneous mixture was added 
CuBr-Me2S (0.15 g, 0.75 mmol), a solution of methyl oct-2-ynoate (27) (0.77 g, 5 mmol) 
in tetrahydrofuran (18 mL) and hexamethylphosphoramide (2.1 mL, 12 mmol).  The 
reaction mixture was stirred at room temperature and monitored by TLC (1:9 ethyl 
acetate: hexanes, p-anisaldehyde stain, UV light).  The reaction was quenched by 
addition of saturated aqueous ammonium chloride solution.  The organic layer was 
washed with half saturated ammonium hydroxide solution until no blue color appeared in 
the wash.  The organic layer was then washed with water and brine, dried over MgSO4. 
Solvent was removed under reduced pressure to leave a yellow oil.  1H NMR of the crude 
mixture showed the alkyne starting material present as well as many other peaks.  The 
product was purified by flash chromatography (1:3 ethyl acetate: hexanes) to give 28 as a 
light yellow oil (0.17 g, 16%). 1H NMR (CDCl3 400 MHz): δ 0.78-0.81 (m, 3 H); 1.22-
1.25 (m, 4 H); 1.38-1.50 (m, 2 H); 2.36-2.39 (m, 2 H); 2.56-2.57 (m, 2 H); 2.63-2.65 (m, 
2H); 3.73 (s, 3 H). 13C NMR (CDCl3 100 MHz): δ 14.2, 22.7, 27.8, 30.8, 32.2, 33.0, 35.3, 
52.3, 133, 164, 190, 204.  The 1H NMR of the (1-ethyoxycyclopropoxy)-trimethylsilane 
and methyl octynoate starting materials are found in the appendix as O and P 
respectively.  The 1H and 13C NMR for the product 28 are found in the appendix as Q and 
R respectively. 
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Synthesis of ethyl 4-oxoundec-5-en-2-ynoate (19) 
OH
C5H11
EtO2C Jones' Reagent
acetone
O
C5H11
EtO2C6 19
 
To an oven dried round bottom flask was added ethyl 4-hydroxyundec-5-en-2-ynoate (6) 
(0.15 g, 0.67 mmol) and acetone (2.7 mL).  This mixture was stirred and Jones’ reagent 
(0.22 mL, 0.74 mmol) was added dropwise.  Upon addition of the first drop of Jones’ 
reagent, the solution changed from clear yellow to clouded greenish yellow.  With each 
subsequent drop of Jones’ reagent, the solution turned more green.  The mixture was 
allowed to stir for 5 minutes.  After 5 minutes a green solid had precipitated, however 
there was still evidence of starting material by TLC analysis (1:9 ethyl acetate: hexanes, 
p-anisaldehye stain, UV light).  The mixture was stirred for an additional 20 minutes, but 
no change in TLC was observed.  The reaction was quenched with methanol, water was 
added, and the organic layer was extracted with ether (2 x 20 mL).  The combined 
organic layers were washed with water, brine, and dried over MgSO4. The solvent was 
removed under reduced pressure to give a yellow oil.  1H NMR of the crude mixture 
showed desired product 19 and minor impurities.  The yellow oil (0.14 g, 93 %) was used 
directly in the next step without further purification. 1H NMR (CDCl3 400 MHz): δ 0.73-
0.76 (m, 3H); 1.15-1.21 (m, 11 H); 4.11-4.20 (m, 2 H); 6.05 (d, 1 H, J = 15.6 Hz); 7.05-
7.12 (m, 1 H).  The 1H NMR of the product 19 is found in the appendix as S. 
Evaluation notes were added to the output document. To get rid of these notes, please order your copy of ePrint IV now.
 34 
Synthesis of (R)-N-(1-phenylethyl)propiolamide (16) 
HOOC H
N-hydroxysuccinimide
DCC, dimethoxyethane
N
O
O
H
O
O
Intermediate a
N
O
O
H
O
O
Intermediate a
NH2
N
H
O
H
14
15
16  
To an oven dried round bottom flask was added dimethoxyethane (10 mL), propiolic acid 
(14) (0.89 mL, 14 mmol), N-hydroxysuccinimide (1.6 g, 14 mmol) and solid 
dicyclohexylcarbodiimide (DCC) (3.0 g, 14 mmol).  Upon addition of DCC, an 
exothermic reaction ensued resulting in precipitation of a solid.  An additional 10 mL of 
dimethoxyethane was added to facilitate stirring.  The reaction mixture was allowed to 
stir under dry nitrogen for 18 hours.  The precipitate was filtered and the solvent removed 
to give the unstable intermediate a as a yellow oil.  This oil was used without further 
purification.  To a stirred solution of intermediate a (2.1 g, 14 mmol) in dichloromethane 
(6 mL) was added dropwise (R)-1-phenylethanamine (15) (1.5 g, 13 mmol).  Upon 
addition of the amine, the reaction mixture heated up.  The brown solution was allowed 
to stir for 24 hours and was then washed with 10 % aqueous sodium carbonate and 1 N 
HCl.  The organic layer was dried over sodium sulfate and the solvent removed under 
reduced pressure to give a brown oil (3.8 g).  1H NMR of the crude mixture showed 
presence of the desired product 16.  The crude product was purified by flash 
chromatography with chloroform as an eluent.  About 5% (0.10 g) of the theoretical yield 
of product was recovered from this purification.  mp 86-88 °C. 1H NMR (CDCl3 400 
MHz): 1.54-1.56 (m, 3 H); 2.79 (s, 1 H); 5.15-5.22 (m, 1 H); 6.22 (s (br), 1 H); 7.28-7.40 
(m, 5 H).  The 1H NMR data of the DCC, (R)-1-phenylethanamine, N-
hydroxysuccinimide, and propiolic acid starting materials is found in the appendix as T, 
U, V, and W respectively.  The 1H NMR of the product (16) is found in the appendix as 
X. 
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